MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$16,158K
Free Cash flow
-$60,927K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Accounts payable and accrued lia...
Proceeds from milestone obligati...
Others
Negative Cash Flow Breakdown
Total segment operating expenses...
Accounts receivable
Total segment operating expenses...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
33,658
22,681
28,087
32,501
Total segment operating expenses-Cost Of Goods Sold
12,846
6,286
6,154
-
Total segment operating expenses-Clinical
1,951
1,783
1,431
-
Total segment operating expenses-Development
1,886
1,726
1,373
-
Total segment operating expenses-Medical Affairs
1,338
1,214
1,230
-
Total segment operating expenses-Selling And Marketing Expense
-
55,959
46,342
-
Total segment operating expenses-Sales And Marketing
108,839
-
-
-
Total segment operating expenses-General And Administrative Expense
-
8,377
7,365
-
Total segment operating expenses-General And Administrative
20,092
-
-
-
Total segment operating expenses-Share-Based Compensation
-
7,423
5,737
-
Total segment operating expenses-Stock-Based Compensation
19,818
-
-
-
Total segment operating expenses-Other Expense
-
58
-80
-
Total segment operating expenses-Other Segment Operating Expenses
170
-
-
-
Total segment operating expenses
-
-
-
85,693
Interest income
1,605
1,968
10,669
-
Loss from operations
-
-
-
-53,192
Interest expense
2,479
2,441
2,599
-
Other income, net
-
-
-
2,041
Income tax (benefit) expense
-
-
-80
-
Net loss
-62,339
-60,618
-41,324
-51,151
Stock-based compensation expense
12,395
7,423
5,737
5,689
Provision for inventory reserve
-
-
0
0
Depreciation and amortization expense
416
397
417
391
Accretion on investments, net of amortization
650
990
1,003
1,092
Other non-cash items
-2,086
-245
-151
-186
Accounts receivable
20,630
839
-11,177
14,007
Inventories
-13
294
9,717
-963
Prepaid expenses and other assets
2,714
524
-284
-1,069
Donation of equipment
-
-
-
0
Accounts payable and accrued liabilities
10,524
10,315
-9,064
10,964
Operating lease right-of-use asset and lease liability, net
-
-
-
-4
Contract liability
-28
-61
-55
-55
Net cash and cash equivalents used in operating activities
-60,927
-44,946
-43,485
-47,047
Purchases of short-term investments, available-for-sale
19,912
14,709
48,886
127,424
Maturities of short-term investments, available-for-sale
-
42,500
75,000
88,500
Payments of milestone obligations under license agreements
-
-
2,000
5,860
Proceeds from maturities and sales of short-term investments, available-for-sale
103,984
-
-
-
Purchases of property and equipment
0
0
0
197
Net cash and cash equivalents provided by investing activities
41,572
27,791
24,114
-44,981
Proceeds from term loan, net of issuance costs
-
-
-1,493
97,750
Payment of term loan issuance costs to third parties
-
-
-
761
Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability
-
-
83
2,577
Proceeds from royalties earned under license agreements recognized as an increase to the financing liability
-
97
-
-
Proceeds from milestone obligations met and royalties earned under license agreements recognized as an increase to the financing liability
2,508
-
-
-
Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan
786
62
1,780
479
Net cash and cash equivalents provided by financing activities
3,197
159
1,131
100,045
Net (decrease) increase in cash and cash equivalents
-16,158
-16,996
-18,240
8,017
Cash and cash equivalents at beginning of period
24,321
41,317
59,557
50,817
Cash and cash equivalents at end of period
8,163
24,321
41,317
59,557
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
and sales of...
$103,984K
Proceeds from milestone
obligations met and...
$2,508K
Proceeds from exercise of
common stock options...
$786K
(-77.03%↓ Y/Y)
Net cash and cash
equivalents provided by...
$41,572K
(-46.45%↓ Y/Y)
Net cash and cash
equivalents provided by...
$3,197K
(-6.58%↓ Y/Y)
Canceled cashflow
$62,412K
Net (decrease)
increase in cash and cash...
-$16,158K
(-2334.85%↓ Y/Y)
Canceled cashflow
$44,769K
Stock-based compensation
expense
$12,395K
(16.18%↑ Y/Y)
Accounts payable and
accrued liabilities
$10,524K
(-38.02%↓ Y/Y)
Other non-cash items
-$2,086K
Depreciation and
amortization expense
$416K
(-25.58%↓ Y/Y)
Inventories
-$13K
(-100.10%↓ Y/Y)
something is missing
-$42,500K
Purchases of short-term
investments,...
$19,912K
(-69.70%↓ Y/Y)
Net cash and cash
equivalents used in...
-$60,927K
(24.16%↑ Y/Y)
Canceled cashflow
$25,434K
something is missing
$71,817K
Total revenue
$33,658K
(42.08%↑ Y/Y)
Interest income
$1,605K
Net loss
-$62,339K
(20.91%↑ Y/Y)
Canceled cashflow
$107,080K
Accounts receivable
$20,630K
(43.51%↑ Y/Y)
Prepaid expenses and
other assets
$2,714K
(289.38%↑ Y/Y)
Accretion on investments,
net of amortization
$650K
(-81.04%↓ Y/Y)
Contract liability
-$28K
(88.33%↑ Y/Y)
Total segment
operating expenses-Sales...
$108,839K
Total segment
operating...
$20,092K
Total segment
operating...
$19,818K
Total segment
operating expenses-Cost...
$12,846K
(111.35%↑ Y/Y)
Interest expense
$2,479K
Total segment
operating...
$1,951K
(-20.50%↓ Y/Y)
Total segment
operating...
$1,886K
(-42.00%↓ Y/Y)
Total segment
operating...
$1,338K
(-33.70%↓ Y/Y)
Total segment
operating expenses-Other...
$170K
Buy us a coffee
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)